- Novartis (NVS) receives approval in Australia for its Bexsero vaccine for protecting infants against MenB, a major cause of meningitis, adding to authorization in Europe. The drug is now licensed in over 30 countries.
- In Australia, Bexsero is approved for children aged two months and older. (PR)
- Meanwhile, Novartis has opened an internal probe into accusations by a former employee in China that she was instructed to bribe doctors by her manager in order to meet sales targets.
Australia OKs Novartis' Bexsero meningitis vaccine
Aug 15 2013, 08:19 ET